Boston, United States
Corium is a biopharmaceutical company that has been leading the development, manufacturing, and commercialization of central nervous system (CNS) therapies since 1999. The company collaborates with some of the world's largest pharmaceutical and consumer product companies to take products from concept through development to manufacturing and final commercialization.
Corium's commitment to developing CNS healthcare therapies aims to provide clinicians with important treatment options for patients, their families, and caregivers. The recent Private Equity Round investment on 20 October 2022 from Gurnet Point Capital and Webster Equity Partners further exemplifies the confidence of investors in the company's vision and potential for growth.
As a commercial-stage biopharmaceutical company, Corium is positioned to make significant strides in the biopharma, healthcare, and pharmaceutical industries. With its headquarters in the United States, the company's focus on CNS therapies underscores its relevance in addressing critical healthcare needs.
Corium's dedication to advancing innovative therapies and its strategic collaborations reflect its strong trajectory in the biopharmaceutical landscape. The recent investment reaffirms its potential to bring impactful CNS therapies to the market, positioning the company for continued success and growth.
